{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:50:56Z","timestamp":1764276656520,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.biopha.2012.11.007","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T12:01:18Z","timestamp":1356523278000},"page":"116-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer"],"prefix":"10.1016","volume":"67","author":[{"given":"Ros\u00e1rio","family":"Pinto-Leite","sequence":"first","affiliation":[]},{"given":"Regina","family":"Arantes-Rodrigues","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Cola\u00e7o","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Aura","family":"Cola\u00e7o","sequence":"additional","affiliation":[]},{"given":"C\u00e9u","family":"Costa","sequence":"additional","affiliation":[]},{"given":"V\u00edtor Moreira","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"L\u00facio","family":"Santos","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2012.11.007_bib0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/138955711795049844","article-title":"Interactions between proteins and platinum-containing anti-cancer drugs","volume":"11","author":"Bischin","year":"2011","journal-title":"Mini Rev Med Chem"},{"issue":"15","key":"10.1016\/j.biopha.2012.11.007_bib0010","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2012.11.007_bib0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1258\/ebm.2010.009322","article-title":"Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine","volume":"235","author":"Silva","year":"2010","journal-title":"Exp Biol Med"},{"issue":"12","key":"10.1016\/j.biopha.2012.11.007_bib0020","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1464-410X.2009.08367.x","article-title":"Dual EGFR and VEGFR inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose and sequence dependent manner","volume":"103","author":"Flaig","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.biopha.2012.11.007_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2407-11-135","article-title":"Increased expression of transcription factor TFAP2a correlates with chemosensitivity in advanced bladder cancer","volume":"11","author":"Nordentoft","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2012.11.007_bib0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.critrevonc.2008.06.002","article-title":"Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents","volume":"69","author":"Bellmunt","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.biopha.2012.11.007_bib0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ijc.26475","article-title":"Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells","volume":"131","author":"Tatokoro","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2012.11.007_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-4-35","article-title":"Chemotherapy in advanced bladder cancer: current status and future","volume":"4","author":"Ismaili","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.biopha.2012.11.007_bib0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/era.11.201","article-title":"Molecular mechanisms of cisplatin resistance in bladder cancer","volume":"12","author":"Drayton","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.biopha.2012.11.007_bib0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.26396","article-title":"mTOR as a therapeutic target in patients with gastric cancer","volume":"130","author":"Al-Batran","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2012.11.007_bib0055","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"mTOR inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.biopha.2012.11.007_bib0060","first-page":"133","article-title":"mTOR inhibitor\/proliferation signal inhibitors: entering or leaving the field?","volume":"23","author":"Rostaing","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.biopha.2012.11.007_bib0065","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","article-title":"Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells","volume":"17","author":"Chiong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.11.007_bib0070","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.biopha.2012.11.007_bib0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-08-2166","article-title":"AKT\/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001","volume":"15","author":"Marinov","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.biopha.2012.11.007_bib0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.biopha.2012.11.007_bib0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2011.06.005","article-title":"Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors","volume":"311","author":"Gaur","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.biopha.2012.11.007_bib0090","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.11.007_bib0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jss.2007.03.061","article-title":"Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells","volume":"145","author":"Tang","year":"2000","journal-title":"J Surg Res"},{"issue":"13\u201315","key":"10.1016\/j.biopha.2012.11.007_bib0100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/15287394.2012.690325","article-title":"Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines","volume":"75","author":"Pinto-Leite","year":"2012","journal-title":"J Toxicol Environ Health A"},{"key":"10.1016\/j.biopha.2012.11.007_bib0105","article-title":"In vivo and in vitro effects of RAD001 on bladder cancer","author":"Vasconcelos-N\u00f3brega","year":"2011","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.biopha.2012.11.007_bib0110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00280-011-1734-5","article-title":"A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors","volume":"69","author":"Fury","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.biopha.2012.11.007_bib0115","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/bjc.2012.36","article-title":"Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma","volume":"106","author":"Hirashima","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2012.11.007_bib0120","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.11.007_bib0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10637-009-9269-x","article-title":"The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines","volume":"28","author":"Ma","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.biopha.2012.11.007_bib0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2012.11.007_bib0135","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00120-011-2754-9","volume":"50","author":"Rexer","year":"2011","journal-title":"Urologe A"},{"issue":"11","key":"10.1016\/j.biopha.2012.11.007_bib0140","doi-asserted-by":"crossref","first-page":"e27509","DOI":"10.1371\/journal.pone.0027509","article-title":"S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer","volume":"6","author":"Nawroth","year":"2011","journal-title":"PLoS One"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:50:23Z","timestamp":1760093423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0753332212001217"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2012.11.007","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2012.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}